Navigation Links
CuraGen to Present at The Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
Date:6/6/2008

BRANFORD, Conn., June 6 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) announced today that Dr. Timothy Shannon, President and Chief Executive Officer, will present at The Seventh Annual Needham & Company Biotechnology and Medical Technology Conference on Wednesday, June 11, 2008, at 3:30 p.m. Eastern time. The conference is being held at the New York Palace Hotel in New York, NY.

Access to a live webcast of the presentation will be available from the Investor Relations section of CuraGen's website at http://www.curagen.com. A replay of the webcast will be available after the presentation and archived for 30 days thereafter.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a clinical-stage biopharmaceutical company developing promising approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

CuraGen Contact:

Glenn Schulman, Pharm.D.

Director Medical Communications

gschulman@curagen.com

(888) 436-6642

CRGN-G


'/>"/>
SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. CuraGen Corporation Regains NASDAQ Listing Compliance
2. CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million
3. CuraGen Reports First Quarter 2008 Financial Results
4. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
5. CuraGen Reports Third Quarter 2007 Financial Results
6. CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference
7. Alexion to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
8. The febit science lounge presents: Webinar About Role of Non-Protein-Coding RNA in Human Genome Set for 11 a.m. EDT on June 12
9. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
10. MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
11. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology: